Crizotinib
Price | USD1000.00 |
Packge | 25KG |
- Min. Order:1KG
- Supply Ability:1000KG
- Time:2019-07-06
Product Details
- Product NameCrizotinib
- CAS No.877399-52-5
- EINECS No.1308068-626-2
- MFC21H22Cl2FN5O
- MW450.34
- Appearancepowderwhite to tan
- storage temp. room temp
- Melting point 192 °C
- Boiling point 599.2±50.0 °C(Predicted)
- density 1.47±0.1 g/cm3(Predicted)
CR077
Crizotinib Basic information |
Product Name: | Crizotinib |
Synonyms: | (R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylaMine;[3-[[(R)-1-(2,6-Dichloro-3- fluorophenyl)ethyl]oxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-yl]aMine;2-PyridinaMine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-;Crozotinib;Crizotinib (PF2341066);PF-02341066 Crizotinib;3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine;k-ras(g12c) inhibitor 6 NA Crizotinib |
CAS: | 877399-52-5 |
MF: | C21H22Cl2FN5O |
MW: | 450.343 |
EINECS: | 1308068-626-2 |
Product Categories: | Inhibitor;Anti-cancer & immunity;Aromatic;Chiral Reagents;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pfizer Compounds;Pharmaceuticals |
Mol File: | 877399-52-5.mol |
Crizotinib Chemical Properties |
Safety Information |
Safety Statements | 24/25 |
HazardClass | IRRITANT |
HS Code | 29333990 |
Crizotinib Usage And Synthesis |
Biological Activity | Potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable. |
Mechanism of action | Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in the activation and dysregulation of the gene's expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrates concentration-dependent inhibition of ALK and c-Met phosphorylation in cell-based assays using tumor cell lines, and also demonstrates antitumor activity in mice bearing tumor xenografts that express EML4-or NPM-ALK fusion proteins or c-Met.Crizotinib is a multitargeted small molecule tyrosine kinase inhibitor, which had been originally developed as an inhibitor of the mesenchymal epithelial transition growth factor (c-MET); it is also a potent inhibitor of ALK phosphorylation and signal transduction. This inhibition is associated with G1-S phase cell cycle arrest and induction of apoptosis in positive cells in vitro and in vivo. Crizotinib also inhibits the related ROS1 receptor tyrosine kinase. References https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876666/ |
side effects | crizotinib (Xalkori) is an oral receptor tyrosine kinase inhibitor indicated for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Common side effects with Xalkori use include upper respiratory infection, nausea, vomiting, stomach pain, decreased appetite, insomnia, dizziness, tired feeling, diarrhea, constipation, rash or itching, cold symptoms (stuffy nose, sneezing, sore throat), numbness or tingling, or swelling in your hands or feet. http://www.rxlist.com/xalkori-side-effects-drug-center.htm |
Chemical Properties | White Solid |
Uses | A potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). A potential antitumor agent. |
Uses | Crizotinib is a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent. |
Uses | PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley |
Definition | ChEBI: A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients wi h locally advanced or metastatic non-small cell lung cancer (NSCLC) |
Crizotinib Preparation Products And Raw materials |
Company Profile Introduction
Henan CoreyChem Co., Ltd, based on the original Zhengzhou Cote Chemical Research Institute, be brave in absorbing highly educated talents & overseas returnees; actively responded to Zhengzhou City High-tech Zone Government’s Special Care Policy, reorganized and founded in National University of Science and Technology Park, which is a high-tech, stock enterprise of high-end chemical Custom synthesis;The park was created by the People's Government of Henan Province, and proved by Ministry of Education and the National Science & Technology, taking the construction mode of "many college a park, and common development", mainly depends on Zhengzhou University and Henan University’s scientific research and talent advantage to set up Universities, scientific research institute and enterprise scientific research achievements transformation platform, to make high-tech enterprises incubate, is the new high-tech talent gathering base, high and new technology industry enterprise radiation base, colleges and universities technological innovation base.
Henan Coreychem Co., Ltd, facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Corey have well-equipped machine, strong technical force and considerate marketing team service. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.
Recommended supplier
-
VIP1年
- AKASH PHARMA EXPORTS
- Crizotinib 99%
- Inquiry
- 2024-05-16
-
VIP1年
- Aspen Biopharma Labs Pvt Ltd
- 877399-52-5 98%
- Inquiry
- 2024-03-16
-
VIP1年
- Apicore Pharmaceuticals Pvt Ltd
- Crizotinib 98%
- Inquiry
- 2024-03-07
-
VIP1年
- Shreyaa Medilife Private Limited
- 877399-52-5 98%
- Inquiry
- 2024-03-04
-
VIP1年
- Rivashaa Agrotech Biopharma Pvt. Ltd.
- 877399-52-5 Crizotinib 98%
- Inquiry
- 2024-01-25
-
VIP1年
- Apothecon Pharmaceuticals Pvt Ltd
- Crizotinib 877399-52-5 99%
- Inquiry
- 2024-01-11
-
VIP2年
- AVD pharmaceuticals Pvt Ltd
- 877399-52-5 98%
- Inquiry
- 2023-09-11
- Since:2014-12-17
- Address: No.967,15th Floor,Unit 7, Building 1, No.70 of DianChang Road, High-tech Development Zone, Zhengzho
INQUIRY